Abstract | PURPOSE: METHODS: Inpatients who developed mucositis severe enough to require PCA treatment were randomized double-blind to a 2-day trial on eszopiclone or placebo-administered at bedtime. Patients completed questionnaires which assessed sleep, pain, and fatigue. PCA medication was calculated in terms of morphine equivalents. Data were analyzed with unpaired t tests and repeated measures analysis of variance. RESULTS: Twenty-two patients were randomized to placebo and 23 to eszopiclone. Groups were comparable in age and treatment characteristics. Mean pain scores were lower in the eszopiclone group at all time points (morning p = 0.01, afternoon p = 0.04, evening p = 0.04). The eszopiclone group reported increased sleep time (p < 0.05), fewer nighttime awakenings (p < 0.001), better self-reported sleep quality (p = 0.01), and depth (p = 0.04). There were no significant differences between eszopiclone and placebo in terms of self-reports of fatigue or opioid usage. CONCLUSION:
|
Authors | Joel E Dimsdale, Edward D Ball, Ewa Carrier, Mark Wallace, Peter Holman, Carolyn Mulroney, Farah Shaikh, Loki Natarajan |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 19
Issue 12
Pg. 2015-20
(Dec 2011)
ISSN: 1433-7339 [Electronic] Germany |
PMID | 21116652
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Azabicyclo Compounds
- Hypnotics and Sedatives
- Piperazines
- Eszopiclone
|
Topics |
- Adult
- Azabicyclo Compounds
(administration & dosage, therapeutic use)
- Eszopiclone
- Fatigue
(chemically induced)
- Hematologic Neoplasms
(complications)
- Humans
- Hypnotics and Sedatives
(administration & dosage, therapeutic use)
- Middle Aged
- Mucositis
(complications, etiology, physiopathology)
- Pain
(drug therapy, etiology)
- Piperazines
(administration & dosage, therapeutic use)
- Sleep
(drug effects)
- Surveys and Questionnaires
|